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alterations that typically appear in congenitally athymic 
(nude) mice, taken as a suitable model of neuroendocrine 
and reproductive aging. The present article briefly reviews 
the literature on the physiology of the thymulin-pituitary 
axis as well as on the new molecular tools available to exploit 
the therapeutic potential of thymulin. 
 Copyright © 2011 S. Karger AG, Basel 
 The Endocrine Thymus and Thymulin 
 In mammals, the interaction of the thymus gland with 
the neuroendocrine system seems to be particularly im-
portant during perinatal life, when the thymus and the 
neuroendocrine system influence the maturation of each 
other  [1] . This was initially suggested by early findings 
showing that in species in which neonatal thymectomy 
does not produce any evident impairment of the immune 
capacity  [2] , neuroendocrine functions are already high-
ly developed at birth  [3] . In mice, the importance of the 
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 Abstract 
 Thymulin is a thymic hormone exclusively produced by the 
thymic epithelial cells. After its discovery and initial charac-
terization in the 1970s, it was demonstrated that thymulin 
production and secretion is strongly influenced by the neu-
roendocrine system. Conversely, a growing core of informa-
tion, to be reviewed here, points to thymulin as a hypophy-
siotropic peptide. Additionally, thymulin was shown to pos-
sess anti-inflammatory and analgesic properties in the brain. 
In recent years, a synthetic DNA sequence coding for a bio-
logically active analog of thymulin, metFTS, was constructed 
and cloned in different adenoviral vectors. These include bi-
directional regulatable Tet-Off vector systems that simulta-
neously express metFTS and green fluorescent protein and 
that can be downregulated reversibly by the addition of the 
antibiotic doxycycline. A number of recent studies suggest 
that thymulin gene therapy may be a suitable therapeutic 
strategy to prevent some of the endocrine and reproductive 
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thymus for a proper maturation of the neuroendocrine 
system is revealed by the endocrine alterations caused by 
neonatal thymectomy or congenital absence of the thy-
mus. In effect, congenitally athymic (nude) female mice 
show significantly reduced levels of circulating and pitu-
itary gonadotropins, a fact that seems to be causally re-
lated with a number of reproductive derangements de-
scribed in these mutants  [4] . Thus, in homozygous (nu/
nu) females, the times of vaginal opening and first ovula-
tion are delayed  [5] , fertility is reduced  [4] and follicular 
atresia is increased such that premature ovarian failure 
results  [6] . Similar abnormalities result from neonatal 
thymectomy of normal female mice  [7, 8] . Ovaries of 
athymic mice respond normally to exogenous gonadotro-
pins, suggesting that the defect is at the level of the hypo-
thalamo-pituitary axis  [9, 10] . In homozygous adult nude 
CD-1 male mice, thyrotropin, prolactin (PRL), growth 
hormone (GH) and gonadotropin responses to immobi-
lization and cold stress are reduced as are serum basal 
levels of the same hormones as compared to the hetero-
zygous counterparts  [11–13] . A functional impairment of 
the hypothalamo-adrenal axis has been reported in nude 
mice suggesting that humoral thymic factors may play a 
role in the maturation of this axis  [14] .
 Thymulin is a thymic metallopeptide involved in sev-
eral aspects of intra- and extrathymic T cell differentia-
tion  [15] . Thymulin, which is exclusively produced by the 
thymic epithelial cells (TEC)  [16] , consists of a biologi-
cally inactive nonapeptide component termed FTS (an 
acronym for serum thymus factor in French), coupled in 
an equimolecular ratio to the ion zinc  [17] , which confers 
biological activity to the molecule  [18] . The metallopep-
tide active form bears a specific molecular conformation 
that has been evidenced by nuclear magnetic resonance 
 [19] .
 Neuroendocrine Control of Thymulin Production 
 Thymulin exerts a controlling feedback effect on its 
own secretion both in vivo and in vitro  [20, 21] . Addition-
ally, thymulin production and secretion is influenced di-
rectly or indirectly by the neuroendocrine system  [22] . A 
particularly relevant pituitary hormone is GH which can 
influence thymulin synthesis and secretion. In vitro , hu-
man GH can stimulate thymulin release from TEC lines 
 [23] which are known to possess specific receptors for GH 
 [24] . Animal studies have shown that treatment of aged 
dogs with bovine GH partially restored their low thymu-
lin serum levels  [25] . In old mice, treatment with ovine 
GH increased their low circulating thymulin levels and 
enhanced the concanavalin-A-dependent proliferative 
response of their thymocytes, as well as interleukin-6 
production  [26] . In old rats, combined treatment with GH 
and thyroxine (T 4 ) was also able to partially restore their 
reduced thymulin levels  [27] . In clinical studies, it was 
reported that in congenitally GH-deficient children, who 
consistently exhibited low plasma thymulin levels, GH 
therapy succeeded in increasing thymic hormone levels 
to near-normal values  [28] . Acromegalic middle-aged pa-
tients have elevated thymulin serum levels compared to 
age-matched normal subjects  [23, 28] . It is likely that 
these effects of GH are mediated, at least in part, by insu-
lin-like growth factor 1 as suggested by the fact that the 
GH-induced enhancement of thymulin production could 
be prevented by previous treatment with antibodies 
against insulin-like growth factor 1 or insulin-like growth 
factor 1 receptor  [23] .
 There is also evidence for a PRL-thymulin axis. Thus, 
it is known that TEC possess PRL receptors  [29] and that 
PRL can stimulate thymulin synthesis and secretion both 
in vitro and in vivo  [30] . Furthermore, administration of 
PRL to old mice elevated their reduced circulating levels 
of thymulin  [30] .
 The thyroid axis also influences thymulin secretion. 
Thus, T 4 has been shown to stimulate thymulin synthesis 
and secretion in mice  [31] . In vivo  treatment of mice with 
 triiodothyronine enhanced thymulin secretion whereas 
treatment of the animals with propylthiouracil, an in-
hibitor of thyroid hormone synthesis, decreased their cir-
culating thymulin levels  [32] . In humans, hyperthyroid-
ism brings about an increase in circulating thymulin lev-
els whereas hypothyroid patients show depressed levels of 
this thymic hormone  [33] . In in vitro studies, it was shown 
that thyroid hormones stimulate thymulin secretion by a 
direct action on TEC  [34, 35] . Interestingly, it has been 
shown that treatment of aged animals with T 4 can reverse 
their decreased thymulin levels  [31] .
 Although there are no studies documenting a direct 
effect of gonadotropins or adrenocorticotropic hormone 
on thymulin secretion, gonadectomy or adrenalectomy 
in mice are known to induce a transient decrease in se-
rum thymulin levels  [36] . This effect is potentiated by the 
simultaneous removal of the adrenals and gonads  [36] . In 
TEC cultures, it was shown that exposure to physiological 
levels of glucocorticoids or gonadal steroids enhanced 
thymulin concentration in the cell supernatants  [37] .
 Although there is no rigorous evidence proving the 
existence of hypothalamic factors able to influence thy-
mulin production by a direct action on TEC, there are 
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two studies which suggest that this may be the case. Treat-
ment of old mice with hypothalamic extracts from young 
mice resulted in reappearance of detectable levels of cir-
culating thymulin  [38] . Hypothalamic and pituitary ex-
tracts from young mice stimulated thymulin release from 
TEC cultures but this stimulation declined when the pi-
tuitary and hypothalamic extracts were obtained from 
old mice  [39] .
 Hypophysiotropic Activity of Thymulin 
 The multilateral influence that the neuroendocrine 
system exerts on thymulin secretion suggests that this 
metallopeptide could in turn be part of a feedback loop 
acting on neuroendocrine structures. This possibility is 
now supported by a significant body of evidence indicat-
ing that thymulin possesses hypophysiotropic activity . 
Thus, thymulin has been shown to stimulate luteinizing 
hormone (LH) release from perfused rat pituitaries  [40] 
and adrenocorticotropic hormone from incubated rat pi-
tuitary fragments, the latter being an effect mediated by 
intracellular cyclic adenosine monophosphate and cyclic 
guanosine monophosphate accumulation  [41] . In an in 
vitro study using pituitary cells obtained from female rats 
in different days of the estrous cycle it was observed that 
thymulin modulates the stimulatory activity of gonado-
tropin-releasing hormone on LH and follicle-stimulating 
hormone release  [42] . Thymulin has been found to stim-
ulate GH, PRL, thyrotropin and gonadotropin release in 
dispersed rat pituitary cells at doses from 10 –8 to 10 –3  M 
 [43–45] , whereas others have reported that thymulin dos-
es of 10 –11  M stimulate LH, inhibit PRL release and have 
no effect on GH secretion in incubated rat pituitary frag-
ments  [41] . The stimulatory effect of thymulin on hor-
mone release in rat pituitary cells declines with the age of 
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 Fig. 1. Diagrammatic representation of the genome of a regulat-
able bidirectional Tet-Off plasmid system expressing the genes for 
GFP and metFTS. It harbors two expression cassettes: the pCMV-
tTA cassette (right portion of the genome) expresses the chimeric 
regulatory protein tTA, which binds to the regulatable bidirec-
tional promoter of the bidirectional cassette hGFP-TRE-metFTS 
(left portion of the genome) and activates it inducing the expres-
sion of the transgenes for hGFP and metFTS.  a The active system 
(in the absence of DOX).  c The system now inhibited by DOX. 
TRE = Tetracycline-responsive element; metFTS = metFTS cod-
ing sequence; tTA = chimeric regulatory protein; P min CMV = cy-
tomegalovirus minimal promoter; SV40pA = polyadenylation 
signal. Images correspond to HEK293 cells transfected with a 
plasmid harboring the Tet-Off system for metFTS and GFP in the 
absence ( b ) or in the presence ( d ) of DOX. Magnification:  ! 20. 
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the cell donor, which suggests that aging brings about a 
desensitization of the pituitary gland to thymic signals 
 [43–45] .
 There is in vitro and in vivo evidence suggesting that 
thymulin plays a role in the regulation of female sponta-
neous puberty, possibly through effects on pituitary go-
nadotropin release and ovarian steroidogenesis  [40, 42, 
46–48] . Thymulin also modulates gonadotropin-induced 
testicular steroidogenesis  [49] .
 Immunoneutralization studies have strengthened the 
hypothesis that thymulin is a physiologic mediator of the 
perinatal influence of the thymus on neuroendocrine 
maturation. Thus, neonatal immunoneutralization of 
circulating thymulin in otherwise normal C57BL/6 mice 
induced significant morphologic alterations in most an-
terior pituitary endocrine cell populations  [50, 51] as well 
as a reduction in circulating levels of gonadotropins, thy-
rotropin, PRL and GH [ 51, 52 ; unpubl. obs.].
 Construction of Synthetic Genes for Thymulin 
 The prospect of implementing thymic hormone gene 
therapy appears as an interesting avenue of research 
aimed at restoring endocrine thymic activity when thy-
mus function is compromised. However, none of the 
genes coding for the known thymic peptides has been 
cloned, a situation that hinders the implementation of 
gene or other molecular therapies for thymic hormones. 
It was suggested that a possible way to overcome this 
problem could be to construct ‘artificial genes’ coding for 
those thymic peptides whose amino acid sequences were 
short and required no posttranslational processing  [53] . 
This was achieved for thymulin and the corresponding 
DNA sequence was initially cloned in a bacterial plasmid 
 [54] . More recently, a DNA sequence coding for the bio-
logically active FTS analog called metFTS was construct-
ed and cloned in an adenoviral vector termed RAd-met-
FTS  [55] .
 When intramuscularly administered to thymecto-
mized mice and rats (whose circulating levels of thymulin 
are nondetectable), RAd-metFTS induced sustained su-
praphysiological serum levels of biologically active thy-
mulin which remained high for at least 112 days in mice 
 [55] and for over 320 days in rats.  Interestingly, adenovi-
rally mediated expression of the synthetic gene for met-
FTS in the substantia nigra and hypothalamus of adult 
thymectomized rats had a significantly longer duration 
than adenovirally mediated expression of the gene for 
green fluorescent protein (GFP) or  Escherichia coli  b -ga-
lactosidase in the same brain regions  [56] . This phenom-
enon could be due to the anti-inflammatory activity in 
the brain reported for thymulin and some thymulin ana-
logs  [57, 58] . The anti-inflammatory activity could pre-
vent the immune system of the vector-injected animals 
from mounting a destructive response against the trans-
duced cells. The same rationale could explain the long-
term persistence of high concentrations of recombinant 
metFTS in the circulation of RAd-metFTS-injected thy-
mectomized rodents  [55] .
 Regulatable Adenovectors for Thymulin 
 The first adenovector harboring the metFTS sequence 
(RAd-metFTS) expressed its transgene constitutively 
 [55] . More recently, a Tet-Off regulatable bidirectional 
plasmid system expressing the genes for humanized 
green fluo rescent protein (hGFP) and metFTS was con-
structed [unpubl. obs.]. It harbors two expression cas-
 Fig. 2. Effect of neonatal thymulin gene therapy on serum LH and 
follicle-stimulating hormone (FSH) in nude mice. The indicated 
vectors were intramuscularly injected at birth and the animals 
were bled 51–52 days afterwards for serum LH and follicle-stim-
ulating hormone determination. Significance of differences be-
tween RAd-GFP-injected animals (placebo) and RAd-metFTS-
injected counterparts are indicated by  *  p  ! 0.05 or  * *  p  ! 0.01. 
Image used with permission  [52] . 
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settes: a pCMV-tTA cassette that expresses the chimeric 
regulatory protein tTA, which binds to the regulatable 
bidirectional promoter of the bidirectional cassette 
hGFP-TRE-metFTS and activates it, thus inducing the 
expression of the transgenes for hGFP and metFTS. If the 
antibiotic doxycycline (DOX) is added to the medium, it 
binds to an allosteric site on the tTA protein and causes 
it to dissociate from the regulatable promoter thus turn-
ing off transgene expression ( fig. 1 ). A two-viral vector 
version of this system was also constructed. It consists of 
two adenoviral vectors; one, RAd-tTA, expresses the tTA 
regulatory protein and the other, RAd-(hGFP-TRE-
metFTS) bidir , expresses the bidirectional regulatable cas-
sette for GFP and metFTS. When a cell is cotransduced 
by both vector components, RAd-tTA expresses the tTA 
regulatory protein, which binds to the regulatable pro-
moter (P min CMV-TRE-P min CMV) of the second vector 
and activates the expression of both transgenes. If DOX 
is added to the medium, it inhibits transgene expression 
by the mechanism described above. The system was suc-
cessfully tested in cell lines and in the brain and muscle 
[unpubl. obs.].
 These bidirectional vectors allow a ready visualization 
of metFTS expression in tissues and organs by fluores-
cence microscopy (if GFP is expressed, then metFTS also 
is because they are under the control of a single promot-
er). The regulatability by DOX of these vectors allows the 
experimenter to turn off and on transgene expression in 
vivo by respectively adding or removing DOX from the 
drinking water.
 Neonatal Gene Therapy for Thymulin in Nude Mice 
 A single intramuscular injection of RAd-metFTS in 
newborn nude mice (nude mice have undetectable circu-
lating levels of thymulin) elicited long-term restoration of 
serum thymulin in these mutants. This treatment was 
able to prevent the deficits in serum LH and follicle-stim-
ulating hormone that typically appear in adult female 
nudes ( fig. 2 )  [52] . Furthermore, neonatal thymulin gene 
therapy (NTGT) in nude female mice has been found to 
significantly prevent the ovarian dysgenesis that usually 
develops in 70-day-old female nude mice  [59] .
 In nude mice, NTGT has also been shown to partial-
ly prevent the alterations of some of the endocrine cell 
populations that occur in these mutants after puberty. 
Thus, NTGT prevented the reduction in the number of 
gonadotrophs, thyrotrophs and corticotrophs in adult 
nudes  [51, 60, 61] . NTGT also prevented, to a varying 
extent, changes in other histomorphometric parameters 
in the anterior pituitary of adult nudes. Thymulin ad-
ministration to nudes marginally decreased their hypo-
thalamic content of corticotropin-releasing hormone 
and slightly increased the adrenal content of corticoste-
rone of these mutants  [61] . NTGT had the highest histo-
morphometric impact on the gonadotrophic population 
of nudes  [60] .
 Concluding Remarks 
 Thymulin is probably the best characterized of all pu-
tative thymic hormones and seems to play a physiologic 
role in thymus-pituitary communication, particularly 
during perinatal life. Interest in the therapeutic use of 
thymulin flourished during the 1970s and 1980s when 
efforts were almost exclusively focused on using thymu-
lin (and other thymic peptides) for the treatment of auto-
immune and other immunopathologies as well as cancer 
 [62, 63] . Subsequent studies, most of them carried out 
during the last 18 years, established that thymulin is ac-
tive on the hypophysis and the brain. This awareness and 
the recent availability of a synthetic gene for metFTS as 
well as sophisticated viral vectors have opened new ave-
nues for the exploration and eventual exploitation of the 
therapeutic potential of this metallopeptide.
 Acknowledgments 
 Part of the work from our laboratory reviewed here was sup-
ported by NIH grant No. R01AG029798-3, ANPCYT grant No. 
PICT08-36938214 and CONICET grant PIP2378 to R.G.G. and by 
the Argentine Research Council and the Institut National de la 
Santé et de la Recherche Médicale (INSERM), France to M.D. and 
R.G.G. 
 
 References  1 Goya RG: The immune-neuroendocrine ho-
meostatic network and aging. Gerontology 
1991; 37: 208–213. 
 2 Solomon JB: Ontogeny of defined immunity 
in mammals; in Neuberger A, Tatum EL 
(eds): Foetal and Neonatal Immunology. 
Frontiers of Biology. New York, American 
Elsevier Publishing Co, 1971, vol 20, pp 234–
306. 
 3 Jost A: The extent of foetal and endocrine au-
tonomy; in Wolstenholme GEW, O’Connor 
M (eds): Foetal Autonomy. Ciba Foundation 
Symposium. London, J&A Churchill Ltd, 
1969, pp 79–94. 
 Thymulin Gene Therapy in the Pituitary Neuroimmunomodulation 2011;18:350–356 355
 4 Rebar RW, Morandini IC, Erickson GF, Pe-
tze JE: The hormonal basis of reproductive 
defects in athymic mice: diminished gonad-
otropin concentrations in prepubertal fe-
males. Endocrinology 1981; 108: 120–126. 
 5 Besedovsky HO, Sorkin E: Thymus involve-
ment in female sexual maturation. Nature 
1974; 249: 356–358. 
 6 Lintern-Moore S, Pantelouris EM: Ovarian 
development in athymic nude mice. The size 
and composition of the follicle population. 
Mech Ageing Dev 1975; 4: 385–390. 
 7 Michael SD, Taguchi O, Nishizuka Y: Effects 
of neonatal thymectomy on ovarian develop-
ment and plasma LH, FSH, GH and PRL in 
the mouse. Biol Reprod 1980; 22: 343–350. 
 8 Nishizuka Y, Sakakura T: Ovarian dysgene-
sis induced by neonatal thymectomy in the 
mouse. Endocrinology 1971; 89: 889–893. 
 9 Pierpaoli W, Besedovsky HO: Role of the 
thymus in programming of neuroendocrine 
functions. Clin Exp Immunol 1975; 20: 323–
328. 
 10 Lintern-Moore S, Pantelouris EM: Ovarian 
development in athymic nude mice. 3. The 
effect of PMSG and oestradiol upon the size 
and composition of the ovarian follicle pop-
ulation. Mech Ageing Dev 1976; 5: 33–38. 
 11 Goya RG, Cónsole GM, Sosa YE, Gómez 
Dumm CL, Dardenne M: Altered functional 
responses with preserved morphology of go-
nadotrophic cells in congenitally athymic 
mice. Brain Behav Immun 2001; 15: 85–92. 
 12 Goya RG, Sosa YE, Cónsole GM, Dardenne 
M: Altered thyrotropic and somatotropic re-
sponses to environmental challenges in con-
genitally athymic mice. Brain Behav Immun 
1995; 9: 79–86. 
 13 Goya RG, Sosa YE, Cónsole GM, Dardenne 
M: Altered regulation of serum prolactin in 
nude mice. Med Sci Res 1996; 24: 279–280. 
 14 Daneva T, Spinedi E, Hadid R, Gaillard RC: 
Impaired hypothalamo-pituitary-adrenal 
axis function in Swiss nude athymic mice. 
Neuroendocrinology 1995; 62: 79–86. 
 15 Bach JF: Thymulin (FTS-Zn). Clin Immunol 
Allergy 1983; 3: 133–156. 
 16 Dardenne M, Papiernik M, Bach JF, Stutman 
O: Studies on thymus products. 3. Epithelial 
origin of the serum thymic factor. Immunol-
ogy 1974; 27: 299–304. 
 17 Gastinel LN, Dardenne M, Pléau JM, Bach 
JF: Studies on the zinc-binding site to the se-
rum thymic factor. Biochim Biophys Acta 
1984; 797: 147–155. 
 18 Dardenne M, Pléau JM, Nabarra B, Lefran-
cier P, Derrien M, Choay J, Bach JF: Contri-
bution of zinc and other metals to the bio-
logical activity of serum thymic factor. Proc 
Natl Acad Sci USA 1982; 79: 5370–5373. 
 19 Cung MT, Marraud M, Lefrancier P, 
Dardenne M, Bach JF, Laussac JP: NMR 
study of a lymphocyte differentiating thymic 
factor. An investigation of the Zn(II)-nona-
peptide complexes (thymulin). J Biol Chem 
1988; 263: 5574–5580. 
 20 Savino W, Dardenne M, Bach JF: Thymic 
hormones containing cells. 3. Evidence for a 
feed-back regulation of the secretion of the 
serum thymic factor (FTS) by thymic epithe-
lial cells. Clin Exp Immunol 1983; 52: 7–12. 
 21 Cohen S, Berrih S, Dardenne M, Bach JF: 
Feed-back regulation of the secretion of a 
thymic hormone (thymulin) by human thy-
mic epithelial cells in culture. Thymus 1986; 
 8: 109–119. 
 22 Savino W, Dardenne M: Neuroendocrine 
control of thymus physiology. Endocr Rev 
2000; 21: 412–443. 
 23 Timsit J, Savino W, Safieh B, Chanson P, 
Gagnerault MC, Bach JF, Dardenne M: GH 
and IGF-I stimulate hormonal function and 
proliferation of thymic epithelial cells. J Clin 
Endocrinol Metab 1992; 75: 183–188. 
 24 Ban E, Gagnerault MC, Jammes H, Postel-
Vinay MC, Haour F, Dardenne M: Specific 
binding sites for growth hormone in cul-
tured mouse thymic epithelial cells. Life Sci 
1991; 48: 2141–2148. 
 25 Goff BL, Roth JA, Arp LH, Incefy GS: Growth 
hormone treatment stimulates thymulin 
production in aged dogs. Clin Exp Immunol 
1987; 68: 580–587. 
 26 Goya RG, Gagnerault MC, De Moraes MC, 
Savino W, Dardenne M: In vivo effects of 
growth hormone on thymus function in ag-
ing mice. Brain Behav Immun 1992; 6: 341–
354. 
 27 Goya RG, Gagnerault MC, Sosa YE, Bevilac-
qua JA, Dardenne M: Effects of growth hor-
mone and thyroxine on thymulin secretion 
in aging rats. Neuroendocrinology 1993; 58: 
 338–343. 
 28 Mocchegiani E, Paolucci P, Balsamo A, Cac-
ciari E, Fabris N: Influence of growth hor-
mone on thymic endocrine activity in hu-
mans. Horm Res 1990; 33: 248–255. 
 29 Dardenne M, Kelly PA, Bach JF, Savino W: 
Identification and functional activity of pro-
lactin receptors in thymic epithelial cells. 
Proc Natl Acad Sci USA 1991; 88: 9700–9704. 
 30 Dardenne M, Savino W, Gagnerault MC, 
Itoh T, Bach JF: Neuroendocrine control of 
thymic hormonal production. 1. Prolactin 
stimulates in vivo and in vitro the produc-
tion of thymulin by human and murine thy-
mic epithelial cells. Endocrinology 1989; 125: 
 3–12. 
 31 Fabris N, Mocchegiani E: Endocrine control 
of thymic serum factor production in young-
adult and old mice. Cell Immunol 1985; 91: 
 325–335. 
 32 Savino W, Wolf B, Aratan-Spire S, Dardenne 
M: Thymic hormone containing cells. 4. 
Fluctuations in the thyroid hormone levels 
in vivo can modulate the secretion of thymu-
lin by the epithelial cells of young mouse thy-
mus. Clin Exp Immunol 1984; 55: 629–635. 
 33 Fabris N, Mocchegiani E, Mariotti S, Pacini 
F, Pinchera A: Thyroid function modulates 
thymic endocrine activity. J Clin Endocrinol 
Metab 1986; 62: 474–478. 
 34 Villa-Verde DM, de Mello-Coelho V, Farias-
de-Oliveira DA, Dardenne M, Savino W: 
Pleiotropic influence of triiodothyronine on 
thymus physiology. Endocrinology 1993; 
 133: 867–875. 
 35 Mocchegiani E, Amadio L, Fabris N: Neuro-
endocrine-thymus interactions. 1. In vitro 
modulation of thymic factor secretion by 
thyroid hormones. J Endocrinol Invest 1990; 
 13: 139–147. 
 36 Dardenne M, Savino W, Duval D, Kaiserlian 
D, Hassid J, Bach JF: Thymic hormone-con-
taining cells. 7. Adrenals and gonads control 
the in vivo secretion of thymulin and its plas-
matic inhibitor. J Immunol 1986; 136: 1303–
1308. 
 37 Savino W, Bartoccioni E, Homo-Delarche F, 
Gagnerault MC, Itoh T, Dardenne M: Thy-
mic hormone containing cells. 9. Steroids in 
vitro modulate thymulin secretion by hu-
man and murine thymic epithelial cells. J 
Steroid Biochem 1988; 30: 479–484. 
 38 Folch H, Eller G, Mena M, Esquivel P: Neu-
roendocrine regulation of thymus hor-
mones: hypothalamic dependence of ‘facteur 
thymique serique’ level. Cell Immunol 1986; 
 102: 211–216. 
 39 Goya RG, Gagnerault MC, Sosa YE, 
Dardenne M: Reduced ability of hypotha-
lamic and pituitary extracts from old mice to 
stimulate thymulin secretion in vitro. Mech 
Ageing Dev 1995; 83: 143–154. 
 40 Zaidi SA, Kendall MD, Gillham B, Jones MT: 
The release of LH from pituitaries perifused 
with thymic extracts. Thymus 1988–1989; 
 12: 253–264. 
 41 Hadley AJ, Rantle CM, Buckingham JC: 
Thymulin stimulates corticotrophin release 
and cyclic nucleotide formation in the rat an-
terior pituitary gland. Neuroimmunomodu-
lation 1997; 4: 62–69. 
 42 Hinojosa L, García L, Domínguez R, Roma-
no MC, Damián-Matsumura PG, Castillo L, 
Rosas P: Effects of thymulin and GnRH on 
the release of gonadotropins by in vitro pitu-
itary cells obtained from rats in each day of 
estrous cycle. Life Sci 2004; 76: 795–804. 
 43 Brown OA, Sosa YE, Bolognani F, Goya RG: 
Thymulin stimulates prolactin and thyro-
tropin release in an age-related manner. 
Mech Ageing Dev 1998; 104: 249–262. 
 44 Brown OA, Sosa YE, Dardenne M, Pléau J, 
Goya RG: Growth hormone-releasing activ-
ity of thymulin on pituitary somatotropes is 
age dependent. Neuroendocrinology 1999; 
 69: 20–27. 
 45 Brown OA, Sosa YE, Dardenne M, Pléau JM, 
Goya RG: Studies on the gonadotropin-re-
leasing activity of thymulin: changes with 
age. J Gerontol A Biol Sci Med Sci 2000; 
 55:B170–B176. 
 46 Hinojosa L, Chavira R, Dominguez R, Rosas 
P: Effects of thymulin on spontaneous pu-
berty and gonadotrophin-induced ovulation 
in prepubertal normal and hypothymic 
mice. J Endocrinol 1999; 163: 255–260. 
 Reggiani et al. Neuroimmunomodulation 2011;18:350–356356
 47 García L, Hinojosa L, Domínguez R, Chavira 
R, Rosas P: Effects of infantile thymectomy 
on ovarian functions and gonadotrophin-
induced ovulation in prepubertal mice: role 
of thymulin. J Endocrinol 2000; 166: 381–387. 
 48 García L, Hinojosa L, Domínguez R, Chavira 
R, Rosas P: Effects of injecting thymulin into 
the anterior or medial hypothalamus or the 
pituitary on induced ovulation in prepuber-
tal mice. Neuroimmunomodulation 2005; 
 12: 314–320. 
 49 Wise T: In vitro and in vivo effects of thymu-
lin on rat testicular steroid synthesis. J Ste-
roid Biochem Mol Biol 1998; 66: 129–135. 
 50 Camihort G, Luna G, Vesenbeckh S, Ferese 
C, Dardenne M, Goya R, Cónsole G: Mor-
phometric assessment of the impact of serum 
thymulin immunoneutralization on pitu-
itary cell populations in peripubertal mice. 
Cells Tissues Organs 2006; 184: 23–30. 
 51 Martines EV, Reggiani PC, Schwerdt JI, 
Goya RG, Cónsole GM: Thymulin gene ther-
apy prevents the histomorphometric chang-
es induced by thymulin deficiency in the 
thyrotrope population of mice. Cells Tissues 
Organs 2011;194:67–75 
 52 Goya RG, Reggiani PC, Vesenbeckh SM, Plé-
au JM, Sosa YE, Cónsole GM, Schade R, 
Henklein P, Dardenne M: Thymulin gene 
therapy prevents the reduction in circulating 
gonadotropins induced by thymulin defi-
ciency in mice. Am J Physiol Endocrinol 
Metab 2007; 293:E182–E187. 
 53 Goya RG, Cónsole GM, Hereñú CB, Brown 
OA, Rimoldi OJ: Thymus and aging: poten-
tial of gene therapy for restoration of endo-
crine thymic function in thymus-deficient 
animal models. Gerontology 2002; 48: 325–
328. 
 54 Calenda A, Cordonnier A, Lederer F, Le 
DKH, Pleau JM: Production of biologically 
active thymulin in  Escherichia coli through 
expression of a chemically synthesized gene. 
Biotechnol Lett 1988; 10: 155–160. 
 55 Reggiani PC, Hereñú CB, Rimoldi OJ, Brown 
OA, Pléau JM, Dardenne M, Goya RG: Gene 
therapy for long-term restoration of circulat-
ing thymulin in thymectomized mice and 
rats. Gene Ther 2006; 13: 1214–1221. 
 56 Morel GR, Brown OA, Reggiani PC, Hereñú 
CB, Portiansky EL, Zuccolilli GO, Pléau JM, 
Dardenne M, Goya RG: Peripheral and mes-
encephalic transfer of a synthetic gene for the 
thymic peptide thymulin. Brain Res Bull 
2006; 69: 647–651. 
 57 Safieh-Garabedian B, Dardenne M, Pléau 
JM, Saadé NE: Potent analgesic and anti-in-
flammatory actions of a novel thymulin-re-
lated peptide in the rat. Br J Pharmacol 2002; 
 136: 947–955. 
 58 Safieh-Garabedian B, Ochoa-Chaar CI, 
Poole S, Massaad CA, Atweh SF, Jabbur SJ, 
Saadé NE: Thymulin reverses inflammatory 
hyperalgesia and modulates the increased 
concentration of proinflammatory cyto-
kines induced by icv endotoxin injection. 
Neuroscience 2003; 121: 865–873. 
 59 Reggiani PC, Barbeito CG, Flamini MA, Ro-
dríguez SS, Cónsole GM, Dardenne M, Goya 
RG: Neonatal thymulin gene therapy pre-
vents the characteristic ovarian atrophy of 
adult nude mice (abstract). Seventh Meet Int 
Soc Neuroimmunomodulation, Rio de Ja-
neiro, 2008. 
 60 Reggiani PC, Martines E, Ferese C, Goya R, 
Console GM: Morphological restoration of 
gonadotrope population by thymulin gene 
therapy in nude mice. Histol Histopathol 
2009; 24: 729–735. 
 61 Martínes EV, Reggiani PC, Schwerdt JI, 
Goya RG, Cónsole GM: Neonatal thymulin 
gene therapy in nude mice: effects on the 
morphology of the pituitary corticotrope 
population. Histol Histopathol 2011;26:471–
479.  
 62 Bach JF, Dardenne M, Goldstein AL: Clinical 
aspects of thymulin (FTS); in Goldstein AL 
(ed): Thymic Hormones and Lymphokines. 
Basic Chemistry and Clinical Applications. 
New York, Plenum Press, 1984, pp 593–600. 
 63 Sztein MB, Goldstein AL: Thymic hor-
mones – A clinical update. Springer Semin 
Immunopathol 1986; 9: 1–18. 
 
